Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

1.

Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.

Ma J, Li S, Reed K, Guo P, Gallo JM.

J Pharmacol Exp Ther. 2003 Jun;305(3):833-9. Epub 2003 Mar 6.

PMID:
12626639
[PubMed - indexed for MEDLINE]
Free Article
2.

Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470.

Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM.

Cancer Res. 2001 Jul 15;61(14):5491-8.

PMID:
11454697
[PubMed - indexed for MEDLINE]
Free Article
3.

Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.

Zhou Q, Guo P, Gallo JM.

Clin Cancer Res. 2008 Mar 1;14(5):1540-9. doi: 10.1158/1078-0432.CCR-07-4544. Erratum in: Clin Cancer Res. 2008 Aug 15;14(16):5308-9.

PMID:
18316579
[PubMed - indexed for MEDLINE]
Free Article
4.

Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.

Zhou Q, Gallo JM.

Neuro Oncol. 2009 Jun;11(3):301-10. doi: 10.1215/15228517-2008-088. Epub 2008 Oct 29.

PMID:
18971416
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens.

Zhou Q, Guo P, Wang X, Nuthalapati S, Gallo JM.

J Pharmacol Exp Ther. 2007 Apr;321(1):265-75. Epub 2007 Jan 26.

PMID:
17259446
[PubMed - indexed for MEDLINE]
Free Article
6.

Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470.

Devineni D, Klein-Szanto A, Gallo JM.

Cancer Res. 1996 May 1;56(9):1983-7.

PMID:
8616836
[PubMed - indexed for MEDLINE]
Free Article
7.

Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.

Grossman R, Tyler B, Rudek MA, Kim E, Zadnik P, Khan U, Blakeley JO, Pathak AP, Brem H.

Cancer Chemother Pharmacol. 2013 Jul;72(1):93-100. doi: 10.1007/s00280-013-2172-3. Epub 2013 May 7.

PMID:
23649683
[PubMed - indexed for MEDLINE]
8.

Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats.

Roman CD, Choy H, Nanney L, Riordan C, Parman K, Johnson D, Beauchamp RD.

J Surg Res. 2002 Jun 1;105(1):43-7.

PMID:
12069500
[PubMed - indexed for MEDLINE]
9.

Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC.

Vajkoczy P, Menger MD, Goldbrunner R, Ge S, Fong TA, Vollmar B, Schilling L, Ullrich A, Hirth KP, Tonn JC, Schmiedek P, Rempel SA.

Int J Cancer. 2000 Jul 15;87(2):261-8.

PMID:
10861485
[PubMed - indexed for MEDLINE]
10.

The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression.

Litz J, Sakuntala Warshamana-Greene G, Sulanke G, Lipson KE, Krystal GW.

Lung Cancer. 2004 Dec;46(3):283-91.

PMID:
15541812
[PubMed - indexed for MEDLINE]
11.

Flk-1 specific kinase inhibitor (SU5416) inhibited the growth of GS-9L glioma in rat brain and prolonged the survival.

Takamoto T, Sasaki M, Kuno T, Tamaki N.

Kobe J Med Sci. 2001 Aug;47(4):181-91.

PMID:
11733657
[PubMed - indexed for MEDLINE]
Free Article
12.

Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.

Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):678-89.

PMID:
15701856
[PubMed - indexed for MEDLINE]
Free Article
13.

Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.

Middlemas DS, Stewart CF, Kirstein MN, Poquette C, Friedman HS, Houghton PJ, Brent TP.

Clin Cancer Res. 2000 Mar;6(3):998-1007.

PMID:
10741727
[PubMed - indexed for MEDLINE]
Free Article
14.

Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition.

Zhou Q, Guo P, Kruh GD, Vicini P, Wang X, Gallo JM.

Clin Cancer Res. 2007 Jul 15;13(14):4271-9.

PMID:
17634557
[PubMed - indexed for MEDLINE]
Free Article
15.

Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection.

Akbar U, Jones T, Winestone J, Michael M, Shukla A, Sun Y, Duntsch C.

J Neurooncol. 2009 Sep;94(2):203-12. doi: 10.1007/s11060-009-9857-9. Epub 2009 Apr 1.

PMID:
19337695
[PubMed - indexed for MEDLINE]
16.

Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.

Heimberger AB, Archer GE, McLendon RE, Hulette C, Friedman AH, Friedman HS, Bigner DD, Sampson JH.

Clin Cancer Res. 2000 Oct;6(10):4148-53.

PMID:
11051269
[PubMed - indexed for MEDLINE]
Free Article
17.

Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.

Kim JT, Kim JS, Ko KW, Kong DS, Kang CM, Kim MH, Son MJ, Song HS, Shin HJ, Lee DS, Eoh W, Nam DH.

Oncol Rep. 2006 Jul;16(1):33-9.

PMID:
16786120
[PubMed - indexed for MEDLINE]
18.

Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416.

Dowlati A, Robertson K, Radivoyevitch T, Waas J, Ziats NP, Hartman P, Abdul-Karim FW, Wasman JK, Jesberger J, Lewin J, McCrae K, Ivy P, Remick SC.

Clin Cancer Res. 2005 Nov 1;11(21):7938-44.

PMID:
16278419
[PubMed - indexed for MEDLINE]
Free Article
19.

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.

Cancer Res. 2003 Sep 15;63(18):5978-91. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.

PMID:
14522925
[PubMed - indexed for MEDLINE]
Free Article
20.

Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo.

Li L, Lin X, Shoemaker AR, Albert DH, Fesik SW, Shen Y.

Clin Cancer Res. 2006 Aug 1;12(15):4747-54.

PMID:
16899626
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk